SCOPUS
Immuno-Oncology and Technology
Elsevier, United States
Immuno-Oncology and Technology is an academic journal published by Elsevier (United States). Identifiers: eISSN 2590-0188. Indexed in SCOPUS. Metrics: CiteScore 6.8, SJR 2.430, SNIP 0.96. tlooto lists 1,495 papers from this journal.
CiteScore
6.80
Scopus citation metric
SJR
2.430
SCImago rank
SNIP
0.96
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- -
- eISSN
- 2590-0188
- Abbreviation
- -
- Publisher
- Elsevier
- Country
- United States
Web of Science categories
No Web of Science category data available.
Scopus ASJC categories
2723 Immunology and Allergy2730 Oncology
Papers in this journal
Recent papers
- The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma.
2026
- Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy.
2026 · 1 citations
- Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care.
2026 · 2 citations
- The genome takes the wheel: CAR T with built-in circuits
2026
- Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
2026 · 1 citations
Most cited papers
- Non-viral chimeric antigen receptor (CAR) T cells going viral
2023 · 60 citations
- LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
2022 · 36 citations
- MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
2022 · 32 citations
- ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
2022 · 31 citations
- 65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC
2024 · 26 citations